Syngene (established in 1993) as a Biocon subsidiary is India’s first Contract Research Organization (CRO) which expanded later to be an integrated service provider offering end-to-end drug discovery, development, and manufacturing services on a single platform (CRAMS). Total research & manufacturing infrastructure for the company is spread across 1.9 million square feet across locations.
Financial Results:
Syngene International Ltd reported Revenues for Q3FY25 of ₹944.00 Crores up from ₹854.00 Crore year on year, a rise of 10.54%.
Total Expenses for Q3FY25 of ₹781.00 Crores up from ₹741.00 Crores year on year, a rise of 5.4%.
Consolidated Net Profit of ₹131.00 Crores up 16.96% from ₹112.00 Crores in the same quarter of the previous year.
The Earnings per Share is ₹3.26, up 17.69% from ₹2.77 in the same quarter of the previous year.
![](data:image/svg+xml;charset=utf-8,<svg height="781px" width="640px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
